Abstract
Warfarin, unfractionated heparin (UFH), and low-molecular-weight heparins are anticoagulants that have been used for treatment of pulmonary embolism. Currently approved drugs for treatment of venous thromboembolism include UFH, enoxaparin, dalteparin, fondaparinux, warfarin, and rivaroxaban. The advent of newer oral anticoagulants such as rivaroxaban, dabigatran, and apixaban has provided us with alternative therapeutic options for long-term anticoagulation. This article will give an overview of the various anticoagulant drugs, use in various clinical scenarios, data supporting their clinical use, and recommendations regarding duration of anticoagulant therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 159-169 |
Number of pages | 11 |
Journal | Journal of Cardiovascular Pharmacology and Therapeutics |
Volume | 19 |
Issue number | 2 |
DOIs | |
State | Published - Mar 2014 |
Externally published | Yes |
Keywords
- apixaban
- dabigatran
- pulmonary embolism
- rivaroxaban
- warfarin
ASJC Scopus subject areas
- Pharmacology
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)